{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T16:49:27Z","timestamp":1794242967439,"version":"4.9.0"},"reference-count":90,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2016,6,1]],"date-time":"2016-06-01T00:00:00Z","timestamp":1464739200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,7]],"date-time":"2019-11-07T00:00:00Z","timestamp":1573084800000},"content-version":"vor","delay-in-days":1254,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2016,6]]},"DOI":"10.1093\/annonc\/mdw100","type":"journal-article","created":{"date-parts":[[2016,3,8]],"date-time":"2016-03-08T01:39:24Z","timestamp":1457401164000},"page":"998-1005","source":"Crossref","is-referenced-by-count":97,"title":["Ocular toxicities of MEK inhibitors and other targeted therapies"],"prefix":"10.1016","volume":"27","author":[{"given":"N.","family":"Stjepanovic","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.P.","family":"Velazquez-Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.L.","family":"Bedard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1093\/annonc\/mdw100_bb0010","article-title":"Ocular adverse effects of anti-cancer chemotherapy","volume":"1","author":"Singh","year":"2012","journal-title":"J Cancer Ther Res"},{"key":"10.1093\/annonc\/mdw100_bb0015","doi-asserted-by":"crossref","first-page":"11701","DOI":"10.1007\/s13277-014-2660-z","article-title":"EGFR inhibitors and autophagy in cancer treatment","volume":"35","author":"Cui","year":"2014","journal-title":"Tumour Biol"},{"key":"10.1093\/annonc\/mdw100_bb0020","doi-asserted-by":"crossref","first-page":"259","DOI":"10.2174\/1389450053765888","article-title":"Small molecules with EGFR-TK inhibitor activity","volume":"6","author":"Albanell","year":"2005","journal-title":"Curr Drug Targets"},{"key":"10.1093\/annonc\/mdw100_bb0025","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1365-2249.2009.03992.x","article-title":"Anti-epidermal growth factor receptor monoclonal antibodies in cancer therapy","volume":"158","author":"Martinelli","year":"2009","journal-title":"Clin Exp Immunol"},{"key":"10.1093\/annonc\/mdw100_bb0030","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1007\/s00520-012-1645-y","article-title":"Spectrum of ocular toxicities from epidermal growth factor receptor inhibitors and their intermediate-term follow-up: a five-year review","volume":"21","author":"Borkar","year":"2013","journal-title":"Support Care Cancer"},{"key":"10.1093\/annonc\/mdw100_bb0035","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1097\/ICO.0b013e318166f483","article-title":"Persisting corneal erosion under cetuximab (Erbitux) treatment (epidermal growth factor receptor antibody)","volume":"27","author":"Foerster","year":"2008","journal-title":"Cornea"},{"key":"10.1093\/annonc\/mdw100_bb0040","doi-asserted-by":"crossref","first-page":"e532","DOI":"10.1200\/JCO.2011.34.6858","article-title":"Trichomegaly and poliosis of the eyelashes during cetuximab treatment of metastatic colorectal cancer","volume":"29","author":"Rodriguez","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdw100_bb0045","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1093\/annonc\/mdi300","article-title":"Trichomegaly of the eyelashes following treatment with cetuximab","volume":"16","author":"Bouche","year":"2005","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdw100_bb0050","doi-asserted-by":"crossref","first-page":"63","DOI":"10.2165\/11531920-000000000-00000","article-title":"Cetuximab-associated elongation of the eyelashes: case report and review of eyelash trichomegaly secondary to epidermal growth factor receptor inhibitors","volume":"12","author":"Cohen","year":"2011","journal-title":"Am J Clin Dermatol"},{"key":"10.1093\/annonc\/mdw100_bb0055","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1111\/j.1365-2354.2006.00763.x","article-title":"Eye complications of cetuximab therapy","volume":"16","author":"Melichar","year":"2007","journal-title":"Eur J Cancer Care (Engl)"},{"key":"10.1093\/annonc\/mdw100_bb0060","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1111\/j.1365-2230.2008.02842.x","article-title":"Trichomegaly of the eyelashes following treatment with cetuximab","volume":"34","author":"Vaccaro","year":"2009","journal-title":"Clin Exp Dermatol"},{"key":"10.1093\/annonc\/mdw100_bb0065","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1093\/annonc\/mdm116","article-title":"Diffuse punctate keratitis in a patient treated with cetuximab as monotherapy","volume":"18","author":"Specenier","year":"2007","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdw100_bb0070","doi-asserted-by":"crossref","first-page":"224","DOI":"10.3816\/CCC.2006.n.040","article-title":"Ocular toxicity related to cetuximab monotherapy in patients with colorectal cancer","volume":"6","author":"Dranko","year":"2006","journal-title":"Clin Colorectal Cancer"},{"key":"10.1093\/annonc\/mdw100_bb0075","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1158\/1078-0432.CCR-07-1354","article-title":"U.S. Food and Drug Administration approval: panitumumab for epidermal growth factor receptor-expressing metastatic colorectal carcinoma with progression following fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy regimens","volume":"14","author":"Giusti","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdw100_bb0080","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1002\/cncr.22915","article-title":"Panitumumab monotherapy in patients with previously treated metastatic colorectal cancer","volume":"110","author":"Hecht","year":"2007","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdw100_bb0085","first-page":"216","article-title":"Erlotinib-induced episcleritis in a patient with pancreatic cancer","volume":"9","author":"Shahrokni","year":"2008","journal-title":"JOP"},{"key":"10.1093\/annonc\/mdw100_bb0090","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1097\/ICO.0b013e31818fdbc6","article-title":"Persistent corneal epithelial defect associated with erlotinib treatment","volume":"28","author":"Johnson","year":"2009","journal-title":"Cornea"},{"key":"10.1093\/annonc\/mdw100_bb0095","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1038\/sj.eye.6701630","article-title":"Ocular findings in patients with solid tumours treated with the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib (\u2018Iressa\u2019, ZD1839) in phase I and II clinical trials","volume":"19","author":"Tullo","year":"2005","journal-title":"Eye (Lond)"},{"key":"10.1093\/annonc\/mdw100_bb0100","doi-asserted-by":"crossref","DOI":"10.3410\/B2-3","article-title":"Ocular immune privilege","volume":"2","author":"Zhou","year":"2010","journal-title":"F1000 Biol Rep"},{"key":"10.1093\/annonc\/mdw100_bb0105","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1200\/JCO.2010.32.4327","article-title":"Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma","volume":"29","author":"Long","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdw100_bb0110","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.ajo.2014.07.003","article-title":"Ocular toxicity in BRAF mutant cutaneous melanoma patients treated with vemurafenib","volume":"158","author":"Choe","year":"2014","journal-title":"Am J Ophthalmol"},{"key":"10.1093\/annonc\/mdw100_bb0115","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1056\/NEJMoa1412690","article-title":"Improved overall survival in melanoma with combined dabrafenib and trametinib","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdw100_bb0120","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdw100_bb0125","first-page":"391","article-title":"Dabrafenib and its potential for the treatment of metastatic melanoma","volume":"6","author":"Menzies","year":"2012","journal-title":"Drug Des Devel Ther"},{"key":"10.1093\/annonc\/mdw100_bb0130","doi-asserted-by":"crossref","first-page":"77","DOI":"10.2147\/DHPS.S39568","article-title":"New developments in the treatment of metastatic melanoma\u2014role of dabrafenib-trametinib combination therapy","volume":"6","author":"Luke","year":"2014","journal-title":"Drug Healthc Patient Saf"},{"key":"10.1093\/annonc\/mdw100_bb0135","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1158\/1078-0432.CCR-13-2054","article-title":"Dabrafenib and trametinib, alone and in combination for BRAF-mutant metastatic melanoma","volume":"20","author":"Menzies","year":"2014","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdw100_bb0140","first-page":"857519","article-title":"Immune-mediated adverse events associated with ipilimumab ctla-4 blockade therapy: the underlying mechanisms and clinical management","volume":"2013","author":"Tarhini","year":"2013","journal-title":"Scientifica (Cairo)"},{"key":"10.1093\/annonc\/mdw100_bb0145","doi-asserted-by":"crossref","first-page":"6043","DOI":"10.1200\/JCO.2005.06.205","article-title":"Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4","volume":"23","author":"Attia","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdw100_bb0150","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1517\/14728222.2014.980235","article-title":"The PD-1\/PD-L1 pathway: biological background and clinical relevance of an emerging treatment target in immunotherapy","volume":"19","author":"Muenst","year":"2015","journal-title":"Expert Opin Ther Targets"},{"key":"10.1093\/annonc\/mdw100_bb0155","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdw100_bb0160","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S1470-2045(15)70076-8","article-title":"Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial","volume":"16","author":"Weber","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1093\/annonc\/mdw100_bb0165","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa1504627","article-title":"Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer","volume":"373","author":"Brahmer","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdw100_bb0170","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1056\/NEJMoa1501824","article-title":"Pembrolizumab for the treatment of non-small-cell lung cancer","volume":"372","author":"Garon","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdw100_bb0175","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","article-title":"PD-1 blockade in tumors with mismatch-repair deficiency","volume":"372","author":"Le","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdw100_bb0180","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1200\/JCO.2014.59.0703","article-title":"Nivolumab for metastatic renal cell carcinoma: results of a randomized phase II trial","volume":"33","author":"Motzer","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdw100_bb0185","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1038\/nature13904","article-title":"MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer","volume":"515","author":"Powles","year":"2014","journal-title":"Nature"},{"key":"10.1093\/annonc\/mdw100_bb0190","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2015.33.18_suppl.lba101","article-title":"Phase I\/II safety and antitumor activity of nivolumab in patients with advanced hepatocellular carcinoma (HCC): CA209\u2013040","volume":"33","author":"El-Khoueiry","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdw100_bb0195","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2015.33.15_suppl.3011","article-title":"Safety and efficacy of MEDI4736, an anti-PD-L1 antibody, in patients from a squamous cell carcinoma of the head and neck (SCCHN) expansion cohort","volume":"33","author":"Segal","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdw100_bb0200","doi-asserted-by":"crossref","first-page":"5s","DOI":"10.1200\/jco.2014.32.18_suppl.lba9000","article-title":"Efficacy and safety of the anti-PD-1 monoclonal antibody MK-3475 in 411 patients (pts) with melanoma (MEL)","volume":"32","author":"Ribas","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdw100_bb0205","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1200\/JCO.2013.53.0105","article-title":"Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab","volume":"32","author":"Topalian","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdw100_bb0210","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2015.33.15_suppl.8011","article-title":"Phase 1 study of pembrolizumab (pembro; MK-3475) plus ipilimumab (IPI) as second-line therapy for advanced non-small cell lung cancer (NSCLC): KEYNOTE-021 cohort D","volume":"33","author":"Patnaik","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdw100_bb0215","doi-asserted-by":"crossref","first-page":"3277","DOI":"10.1200\/JCO.2011.41.5851","article-title":"Ocular toxicity of targeted therapies","volume":"30","author":"Renouf","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdw100_bb0220","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1007\/s00417-006-0469-1","article-title":"A case of cutaneous melanoma metastatic to the vitreous cavity: possible pathomechanism and review of the literature","volume":"245","author":"Jaissle","year":"2007","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1093\/annonc\/mdw100_bb0225","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s40425-014-0041-1","article-title":"Retinal vasculitis and ocular vitreous metastasis following complete response to PD-1 inhibition in a patient with metastatic cutaneous melanoma","volume":"2","author":"Manusow","year":"2014","journal-title":"J Immunother Cancer"},{"key":"10.1093\/annonc\/mdw100_bb0230","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1007\/s00280-014-2521-x","article-title":"Phase I dose-escalation study of the HSP90 inhibitor AUY922 in Japanese patients with advanced solid tumors","volume":"74","author":"Doi","year":"2014","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1093\/annonc\/mdw100_bb0235","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.taap.2013.09.018","article-title":"A rat retinal damage model predicts for potential clinical visual disturbances induced by Hsp90 inhibitors","volume":"273","author":"Zhou","year":"2013","journal-title":"Toxicol Appl Pharmacol"},{"key":"10.1093\/annonc\/mdw100_bb0240","doi-asserted-by":"crossref","first-page":"3671","DOI":"10.1158\/1078-0432.CCR-12-3404","article-title":"First-in-human phase I dose-escalation study of the HSP90 inhibitor AUY922 in patients with advanced solid tumors","volume":"19","author":"Sessa","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdw100_bb0245","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1001\/jamaophthalmol.2014.409","article-title":"Reversible nyctalopia and retinopathy in a patient with metastatic cancer treated with anti-heat shock protein 90 therapy","volume":"132","author":"Munk","year":"2014","journal-title":"JAMA Ophthalmol"},{"key":"10.1093\/annonc\/mdw100_bb0250","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/35065000","article-title":"Mammalian MAP kinase signalling cascades","volume":"410","author":"Chang","year":"2001","journal-title":"Nature"},{"key":"10.1093\/annonc\/mdw100_bb0255","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1158\/1078-0432.CCR-14-0979","article-title":"First-in-human phase I dose escalation study of a second-generation non-ansamycin HSP90 inhibitor, AT13387, in patients with advanced solid tumors","volume":"21","author":"Shapiro","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdw100_bb0260","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/S0955-0674(97)80061-0","article-title":"Mitogen-activated protein kinase pathways","volume":"9","author":"Robinson","year":"1997","journal-title":"Curr Opin Cell Biol"},{"key":"10.1093\/annonc\/mdw100_bb0265","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1158\/1078-0432.CCR-07-4790","article-title":"Advances in targeting the Ras\/Raf\/MEK\/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy","volume":"14","author":"Friday","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdw100_bb0270","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1056\/NEJMoa1203421","article-title":"Improved survival with MEK inhibition in BRAF-mutated melanoma","volume":"367","author":"Flaherty","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdw100_bb0275","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S1470-2045(13)70024-X","article-title":"MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study","volume":"14","author":"Ascierto","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1093\/annonc\/mdw100_bb0280","doi-asserted-by":"crossref","first-page":"9009","DOI":"10.1200\/jco.2014.32.15_suppl.9009","article-title":"A phase 1b\/2 study of LEE011 in combination with binimetinib (MEK162) in patients with NRAS-mutant melanoma: early encouraging clinical activity","volume":"32","author":"Sosman","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdw100_bb0285","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1038\/nrclinonc.2014.83","article-title":"The clinical development of MEK inhibitors","volume":"11","author":"Zhao","year":"2014","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1093\/annonc\/mdw100_bb0290","doi-asserted-by":"crossref","first-page":"4456","DOI":"10.1200\/JCO.2004.01.185","article-title":"Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer","volume":"22","author":"Rinehart","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdw100_bb0295","article-title":"The biological profile of PD 0325901: a second generation analog of CI-1040 with improved pharmaceutical potential","volume":"45","author":"Sebolt-Leopold","year":"2004","journal-title":"Cancer Res"},{"key":"10.1093\/annonc\/mdw100_bb0300","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1158\/1078-0432.CCR-09-1883","article-title":"Phase I pharmacokinetic and pharmacodynamic study of the oral MAPK\/ERK kinase inhibitor PD-0325901 in patients with advanced cancers","volume":"16","author":"LoRusso","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdw100_bb0305","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1200\/JCO.2007.14.4956","article-title":"Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase 1\/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers","volume":"26","author":"Adjei","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdw100_bb0310","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1158\/1078-0432.CCR-09-2483","article-title":"The first-in-human study of the hydrogen sulfate (Hyd-sulfate) capsule of the MEK1\/2 inhibitor AZD6244 (ARRY-142886): a phase I open-label multicenter trial in patients with advanced cancer","volume":"16","author":"Banerji","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdw100_bb0315","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2011.29.4_suppl.278","article-title":"A phase Ib study of the MEK inhibitor GSK1120212 combined with gemcitabine in patients with solid tumors: Interim results","volume":"29","author":"Tolcher","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdw100_bb0320","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/S1470-2045(12)70270-X","article-title":"Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial","volume":"13","author":"Infante","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1093\/annonc\/mdw100_bb0325","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1016\/j.ejca.2013.03.020","article-title":"A phase 1b study of trametinib, an oral Mitogen-activated protein kinase (MEK) inhibitor, in combination with gemcitabine in advanced solid tumours","volume":"49","author":"Infante","year":"2013","journal-title":"Eur J Cancer"},{"key":"10.1093\/annonc\/mdw100_bb0330","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1159\/000357060","article-title":"Uveitis as a result of MAP kinase pathway inhibition","volume":"4","author":"Joshi","year":"2013","journal-title":"Case Rep Ophthalmol"},{"key":"10.1093\/annonc\/mdw100_bb0335","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/S0140-6736(15)60898-4","article-title":"Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial","volume":"386","author":"Long","year":"2015","journal-title":"Lancet"},{"key":"10.1093\/annonc\/mdw100_bb0340","doi-asserted-by":"crossref","first-page":"4806","DOI":"10.1158\/1078-0432.CCR-12-0742","article-title":"First-in-human, phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of RO5126766, a first-in-class dual MEK\/RAF inhibitor in patients with solid tumors","volume":"18","author":"Martinez-Garcia","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdw100_bb0345","doi-asserted-by":"crossref","first-page":"4794","DOI":"10.1158\/1078-0432.CCR-12-0868","article-title":"Phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of the MEK inhibitor RO4987655 (CH4987655) in patients with advanced solid tumors","volume":"18","author":"Leijen","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdw100_bb0350","doi-asserted-by":"crossref","first-page":"6839","DOI":"10.1158\/0008-5472.CAN-09-0679","article-title":"RDEA119\/BAY 869766: a potent, selective, allosteric inhibitor of MEK1\/2 for the treatment of cancer","volume":"69","author":"Iverson","year":"2009","journal-title":"Cancer Res"},{"key":"10.1093\/annonc\/mdw100_bb0355","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1158\/1078-0432.CCR-12-3529","article-title":"Multicenter phase I trial of the mitogen-activated protein kinase 1\/2 inhibitor BAY 86\u20139766 in patients with advanced cancer","volume":"19","author":"Weekes","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdw100_bb0360","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2011.29.15_suppl.3019","article-title":"Safety and evidence of activity of MSC1936369, an oral MEK1\/2 inhibitor, in patients with advanced malignancies","volume":"29","author":"Houede","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdw100_bb0365","doi-asserted-by":"crossref","first-page":"e105","DOI":"10.1038\/bcj.2013.1","article-title":"MEK inhibitors as a chemotherapeutic intervention in multiple myeloma","volume":"31","author":"Chang-Yew","year":"2013","journal-title":"Blood Cancer J"},{"key":"10.1093\/annonc\/mdw100_bb0370","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1097\/ICB.0000000000000228","article-title":"Pimasertib and serous retinal detachments","volume":"10","author":"AlAli","year":"2016","journal-title":"Retin Cases Brief Rep"},{"key":"10.1093\/annonc\/mdw100_bb0375","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1001\/jamaophthalmol.2014.976","article-title":"Bilateral subfoveal neurosensory retinal detachment associated with MEK inhibitor use for metastatic cancer","volume":"132","author":"McCannel","year":"2014","journal-title":"JAMA Ophthalmol"},{"key":"10.1093\/annonc\/mdw100_bb0380","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2011-4716","article-title":"A first-in-human phase 1 study to evaluate the MEK1\/2 inhibitor GDC-0973 administered daily in patients with advanced solid tumors","volume":"71","author":"Rosen","year":"2011","journal-title":"Cancer Res"},{"key":"10.1093\/annonc\/mdw100_bb0385","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1056\/NEJMoa1408868","article-title":"Combined vemurafenib and cobimetinib in BRAF-mutated melanoma","volume":"371","author":"Larkin","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdw100_bb0390","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2015.33.15_suppl.9033","article-title":"Clinical features of cobimetinib (COBI)-associated serous retinopathy (SR) in BRAF-mutated melanoma patients (pts) treated in the coBRIM study","volume":"33","author":"De La Cruz-Merino","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdw100_bb0395","unstructured":"T Shimokata, K Watanabe, T Shibata et al. Results of a phase 1 study of MEK162, an oral MEK inhibitor, in Japanese patients with advanced solid tumors. Presented at the 38th ESMO Annual Meeting; 27 September\u20131 October, 2013; Amsterdam, Netherlands."},{"key":"10.1093\/annonc\/mdw100_bb0400","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1200\/jco.2014.32.15_suppl.9051","article-title":"A phase 1b dose-escalation study of BYL719 plus binimetinib (MEK162) in patients with selected advanced solid tumors","volume":"32","author":"Juric","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdw100_bb0405","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2013.31.15_suppl.9029","article-title":"Preliminary results from a phase Ib\/II, open-label, dose-escalation study of the oral BRAF inhibitor LGX818 in combination with the oral MEK1\/2 inhibitor MEK162 in BRAF V600-dependent advanced solid tumors","volume":"31","author":"Kefford","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdw100_bb0410","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2015.33.15_suppl.9007","article-title":"A phase Ib\/II study of BRAF inhibitor (BRAFi) encorafenib (ENCO) plus MEK inhibitor (MEKi) binimetinib (BINI) in cutaneous melanoma patients naive to BRAFi treatment","volume":"33","author":"Sullivan","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdw100_bb0415","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1093\/annonc\/mdu169","article-title":"Transient MEK inhibitor-associated retinopathy in metastatic melanoma","volume":"25","author":"Urner-Bloch","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdw100_bb0420","first-page":"673796","article-title":"Bilateral multifocal central serous-like chorioretinopathy due to MEK inhibition for metastatic cutaneous melanoma","volume":"2013","author":"Schoenberger","year":"2013","journal-title":"Case Rep Ophthalmol Med"},{"key":"10.1093\/annonc\/mdw100_bb0425","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1007\/s10637-010-9567-3","article-title":"Dermatologic side effects associated with the MEK 1\/2 inhibitor selumetinib (AZD6244, ARRY-142886)","volume":"29","author":"Balagula","year":"2011","journal-title":"Invest New Drugs"},{"key":"10.1093\/annonc\/mdw100_bb0430","first-page":"21153","article-title":"Acute onset central serous retinopathy in association with Mek inhibitor use for metastatic cancer","volume":"52","author":"Velez-Montoya","year":"2011","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1093\/annonc\/mdw100_bb0435","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/j.ctrv.2013.01.003","article-title":"Effect of inhibition of the FGFR-MAPK signaling pathway on the development of ocular toxicities","volume":"39","author":"van der Noll","year":"2013","journal-title":"Cancer Treat Rev"},{"key":"10.1093\/annonc\/mdw100_bb0440","doi-asserted-by":"crossref","first-page":"771","DOI":"10.3892\/ijmm_00000191","article-title":"MEK\/ERK pathway mediates UVB-induced AQP1 downregulation and water permeability impairment in human retinal pigment epithelial cells","volume":"23","author":"Jiang","year":"2009","journal-title":"Int J Mol Med"},{"key":"10.1093\/annonc\/mdw100_bb0445","doi-asserted-by":"crossref","first-page":"801787","DOI":"10.1155\/2014\/801787","article-title":"Cell models to study regulation of cell transformation in pathologies of retinal pigment epithelium","volume":"2014","author":"Kuznetsova","year":"2014","journal-title":"J Ophthalmol"},{"key":"10.1093\/annonc\/mdw100_bb0450","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1089\/jop.2009.0060","article-title":"PD0325901, a mitogen-activated protein kinase kinase inhibitor, produces ocular toxicity in a rabbit animal model of retinal vein occlusion","volume":"25","author":"Huang","year":"2009","journal-title":"J Ocul Pharmacol Ther"},{"key":"10.1093\/annonc\/mdw100_bb0455","unstructured":"National_Cancer_Institute. Common Terminology Criteria for Adverse Events v4.0.NCI, NIH, DHHS. NIH publication # 09-7473, 29 May 2009."}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419356388?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419356388?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/27\/6\/998\/6677629\/mdw100.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,17]],"date-time":"2023-08-17T04:35:09Z","timestamp":1692246909000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419356388"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6]]},"references-count":90,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2016,6]]}},"alternative-id":["S0923753419356388"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdw100","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2016,6]]}}}